Analysts Offer Predictions for Eli Lilly and Co.’s FY2016 Earnings (LLY)
Eli Lilly and Co. (NYSE:LLY) – Stock analysts at SunTrust Banks cut their FY2016 EPS estimates for Eli Lilly and in a report released on Wednesday. SunTrust Banks analyst J. Boris now forecasts that the brokerage will post earnings per share of $3.51 for the year, down from their previous estimate of $3.60. SunTrust Banks also issued estimates for Eli Lilly and’s FY2019 earnings at $5.05 EPS.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 EPS.
A number of other equities research analysts also recently issued reports on the company. BMO Capital Markets downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. Jefferies Group reissued a “buy” rating and set a $100.00 price target (down previously from $105.00) on shares of Eli Lilly and in a research report on Friday, October 28th. Societe Generale reissued a “hold” rating and set a $78.00 price target on shares of Eli Lilly and in a research report on Thursday, October 27th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 26th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $95.39.
Eli Lilly and (NYSE:LLY) traded down 10.51% during midday trading on Thursday, hitting $68.00. The stock had a trading volume of 53,975,853 shares. The company’s 50-day moving average price is $77.17 and its 200 day moving average price is $77.97. The company has a market capitalization of $71.92 billion, a PE ratio of 29.58 and a beta of 0.28. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be given a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 3.00%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s dividend payout ratio (DPR) is presently 88.70%.
In other news, insider Maria A. Crowe sold 2,248 shares of the firm’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.20% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the stock. Iowa State Bank purchased a new stake in shares of Eli Lilly and during the second quarter valued at approximately $104,000. Tradewinds Capital Management LLC increased its stake in shares of Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares in the last quarter. PineBridge Investments L.P. increased its stake in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Integrated Wealth Management increased its stake in shares of Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares in the last quarter. Finally, Financial Architects Inc increased its stake in shares of Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares in the last quarter. Institutional investors own 75.11% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Analysts Offer Predictions for Eli Lilly and Co.’s FY2016 Earnings (LLY)” was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2016/11/24/analysts-offer-predictions-for-eli-lilly-and-co-s-fy2016-earnings-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.